News

Published on

June 11, 2025

SeqOne and Agilent Announce Strategic Collaboration to Advance Liquid Biopsy Data Analysis for Oncology Applications

SeqOne and Agilent are joining forces to elevate liquid biopsy analysis in oncology optimized for Agilent's Avida Cancer panels¹ inside SeqOne's bioinformatics platform.
SomaMethyl (methylation) will integrate Agilent proprietary Methylation Index
Collaboration aims to equip molecular labs with a seamless, optimized end-to-end workflow for in-house genomic and epigenomic liquid biopsy testing.

‍

New Integrated Solutions, SomaMethyl and SomaLBx, to Provide Optimized Methylation and DNA Sequencing Analysis from Agilent's Avida Panels on SeqOne's Bioinformatics Platform

‍

MONTPELLIER, France – June 11, 2025 – SeqOne today announced a strategic collaboration with Agilent to enhance the analysis of liquid biopsy data for oncology. This partnership will deliver two powerful, integrated solutions, SomaMethyl and SomaLBx, optimized for Agilent's cutting-edge Avida Cancer panels and integrated into SeqOne's advanced bioinformatics platform to provide molecular labs with streamlined and robust data analysis capabilities.

The collaboration aims to empower laboratories and clinical research institutions by simplifying complex data interpretation and accelerating the journey from sample to actionable insights, ultimately supporting improved decision-making in oncology care.

“Agilent’s Avida panels¹ are optimized to detect cell-free DNA (cfDNA) and enable multiomic analysis from a single sample. By partnering with SeqOne's bioinformatics capabilities, we are empowering labs with a complete liquid biopsy workflow to easily translate genomic and epigenomic data into clear, actionable insights,” said Karen Chapman, PhD, Associate VP of R&D, Genomics, Agilent.

‍

SomaMethyl: Innovative Methylation Analysis for Enhanced Liquid Biopsy, Featuring Agilent's Proprietary "Methyl Index" Algorithm

The primary focus of the collaboration is SomaMethyl, an innovative methylation analysis solution that integrates Agilent's proprietary Methylation Index algorithm into SeqOne's state-of-the-art bioinformatics platform. SomaMethyl is designed to enhance liquid biopsy applications, with a strong initial focus on Minimal Residual Disease (MRD) detection. Key features include:

Rapid and accurate methyl-seq data analysis, providing a streamlined, end-to-end workflow from sample processing to final report generation.
Initial support for oncology applications using the Agilent Avida Methyl 3400 DMR Cancer Panel, a panel covering approximately 3,400 differentially methylated regions (DMRs). These regions, identified through internal and public sequencing data, are associated with tumor-specific methylation patterns that distinguish tumor-derived DNA from normal cfDNA.
Future expansions to support custom methylation panels and cohort analysis are planned for later this year.

"SeqOne is proud to further strengthen our valued partnership with Agilent through this new collaboration focused on cfDNA analysis," stated Martin Dubuc, CEO of SeqOne. "Building on our successful joint efforts in Homologous Recombination Deficiency (HRD) and Comprehensive Genomic Profiling (CGP), SomaMethyl represents an exciting expansion of our shared commitment to the oncology community. SomaMethyl unlocks the power of cfDNA methylation for critical applications like MRD detection, providing a pivotal tool for molecular labs and labs willing to embrace in-house methylation profile analysis. SomaMethyl unlocks the power of cfDNA methylation data for critical applications like MRD detection, providing a pivotal tool for molecular labs and labs willing to embrace in-house methylation profile analysis."

‍

SomaLBx: Optimized DNA Sequencing Analysis for Liquid Biopsy

Complementing SomaMethyl, SomaLBx delivers optimized and streamlined DNA sequencing data analysis specifically for liquid biopsy samples processed with Agilent's Avida DNA Cancer Panels. This solution will integrate seamlessly with SeqOne's intuitive platform, enabling molecular labs to:

Efficiently process and analyze complex DNA sequencing data from cfDNA.
Accurately detect a wide range of genomic alterations, including SNVs, indels, CNVs, and fusions, critical for understanding tumor genomics.
Benefit from a rapid and user-friendly workflow, reducing turnaround times and enhancing laboratory productivity.
SomaLBx will be particularly relevant for optimizing Avida Duo analysis workflows, which allow for comprehensive insights by combining DNA sequencing and methylation data from a single sample.

The combined power of SomaMethyl and SomaLBx will enable molecular labs to fully unlock the potential of Agilent's Avida panels. These integrated solutions transform complex multiomic data into actionable genomic insights, particularly enhancing Avida Duo workflows by synergizing methylation and DNA sequencing data for the most comprehensive analysis.

This strategic partnership underscores both companies' commitment to advancing precision oncology by providing comprehensive and user-friendly tools that address the evolving needs of the oncology field worldwide.

‍

¹^{Agilent Avida and SureSelect Cancer products are For Research Use Only. Not for use in diagnostic procedures.}

‍

About SeqOne

SeqOne is a deep-tech company committed to making personalized medicine a reality. Its AI-powered genomic analysis platform provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analysis of genetic data for applications in oncology, rare diseases, and, through recent acquisitions, multi-omics, including pathogen detection. With 140 active lab customers across 22 countries and a projection to process over 110,000 patient analyses in 2025, SeqOne serves a growing global customer base of healthcare providers and biopharmaceutical companies, supported by strong industry partnerships and an expanding presence in the US market. www.seqone.com

‍

About Agilent Technologies‍

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com.

‍

What’s new at SeqOne?

News

May 22, 2025

SeqOne Genomics Raises €20 Million in Oversubscribed Growth Round to Lead AI-Powered NGS Revolution in Personalized Medicine

New capital from Supernova Invest, alongside existing partners Elaia, Omnes, and Merieux Equity Partners, will accelerate SeqOne’s mission to transform genomic diagnostics worldwide, focusing on international expansion, U.S., and strategic growth.

Platform features

May 7, 2025

SeqOne Launches SomaHemato: Advancing Precision in CLL Prognostics with Robust IGHV Mutational Status Analysis on the SeqOne Platform

SeqOne's SomaHemato offers robust, validated IGHV analysis for CLL prognosis, overcoming NGS short-read limits for precise clinical insights.

News

Apr 7, 2025

SeqOne Accelerates Growth and Expansion into Multi-Omics with Life & Soft Acquisition

Strategic acquisition bolsters SeqOne's multi-omics capabilities and expands service offerings with ISO-certified sequencing platform.

Platform features

Feb 10, 2025

Next-Generation Phenotype-Driven Genomic Analysis with SeqOne

SeqOne's DiagAI HPO automates extraction of HPO terms from clinical notes using AI, streamlining phenotype-driven genomic analysis with multi-language support.

Testimonial

Dec 5, 2024

Transforming Patient Care: SeqOne Empowers CHU de Reims with Advanced Genomic Analysis

Professor Anne-Sophie Lèbre of CHU de Reims uses SeqOne for rare disease and oncology genomics, enabling rapid, precise variant interpretation.

Science

Dec 5, 2024

Nanopore adaptive sampling accurately detects nucleotide variants and improves the characterization of large-scale rearrangement for the diagnosis of cancer predisposition

Here, 30 well-characterized clinical germline samples were studied with adaptive sampling to enrich the full sequence of 152 cancer predisposition genes. Sequencing was performed on Oxford Nanopore (ONT) R10.4.1 MinION flowcells with the Q20+ chemistry.

Platform features

Nov 18, 2024

SeqOne’s DiagAI Score Brings Transparency to Genomic Variant Ranking: Unveiling the AI Decision Process with xAI

DiagAI uses inheritance & quality rules based on real diagnostic data, enabling clinicians to understand AI recommendations and collaborate on system improvement.

News

Nov 14, 2024

SeqOne Platform Achieves IVDR Certification, Setting New Quality Standards for Clinical Genomic Analysis

SeqOne Platform gets IVDR Class C medical device certification for NGS analysis in oncology and rare diseases, validating quality and safety.

Case study

Oct 14, 2024

Precision Medicine at Scale: AP-HM’s Automated Exome Analysis Success Story

APHM and SeqOne partner to automate exome sequencing with AI, processing up to 2,000 rare disease samples yearly for better diagnostics.

Platform features

Oct 9, 2024

SeqOne Unveils DiagAI Score: Explainable AI-Powered Variant Ranking

SeqOne launches DiagAI Score, a 0-100 metric for ranking genetic variants' disease-causing potential, combining AI power with human expertise for faster diagnosis.

Science

Sep 30, 2024

Fine mapping of RNA isoform diversity using an innovative targeted long-read RNA sequencing protocol with novel dedicated bioinformatics pipeline

Solving the structure of mRNA transcripts is a major challenge for both research and molecular diagnostic purposes. Current approaches based on short-read RNA sequencing and RT-PCR techniques cannot fully explore the complexity of transcript structure.

Case study

Sep 9, 2024

Case Study: North West GLH Validation and Implementation of In-House HRD testing with SeqOne’s SomaHRD

SeqOne’s HRD platform enables North West GLH to conduct in-house genomic instability testing for ovarian cancer.

News

Jun 17, 2024

MGI Tech and SeqOne Partner to Advance End-to-End Genomic Analysis

MGI and SeqOne partner to develop genomic analysis solutions, combining MGI's sequencing tech with SeqOne's AI-powered platform.

Platform features

Jun 17, 2024

Introducing SeqOne CGH Array Interpretation

SeqOne Cloud now supports Agilent CGH MicroArrays, offering AI-powered CNV annotation, ACMG classification, and seamless Cartagenia migration.

Platform features

Apr 19, 2024

SeqOne GenomeAlert! A variant reevaluation automation agent to improve patient care

GenomeAlert! reevaluates genetic variant classifications monthly against ClinVar to ensure accurate patient diagnoses and treatment.

News

Mar 11, 2024

Oxford Nanopore Technologies and SeqOne Partner to Support Interpretation of Nanopore Sequencing in Clinical Use

A new partnership delivers end-to-end genome nanopore sequencing solutions for clinical applications in rare disease and oncology.

Science

Mar 1, 2024

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD).

News

Jan 30, 2024

SeqOne Genomics appoints Martin Dubuc as Chief Executive Officer

Martin Dubuc appointed as SeqOne Genomics CEO, Nicolas Philippe becomes President & CPSO to drive global clinical genomics expansion.

Platform features

Feb 22, 2023

SeqOne's Clinically Validated HRD Test Enhances Precision in Ovarian Cancer Treatment

SeqOne launches HRD test for ovarian cancer patients, validated with PAOLA-1 cohort. Clinical validation shows comparable survival benefits to Myriad myChoice® CDx.

Science

Nov 21, 2022

Genomic analysis of adult thrombotic microangiopathies in less than 3 days: from rapid to fast genomics to treatment

Using nanopore sequencing, we showed the feasibility and impact of rapid genomic screening for managing thrombotic microangiopathies in 18 prospective cases, achieving diagnoses in <3 days. We compared the results with standard exome sequencing, cost efficiency, and complement blockade initiation.

Science

Sep 22, 2022

Exome sequencing as a first-tier test for copy number variant detection: retrospective evaluation and prospective screening in 2418 cases

Despite the availability of whole exome (WES) and genome sequencing (WGS), chromosomal microarray (CMA) remains the first-line diagnostic test in most rare disorders diagnostic workup, looking for copy number variations (CNVs), with a diagnostic yield of 10%–20%.

Science

Jun 22, 2022

Rapid exome sequencing in critically ill infants: implementation in routine care from French regional hospital's perspective

This monocentric study included fifteen children under a year old in intensive care with suspected monogenic conditions for rapid trio exome sequencing (rES) between April 2019 and April 2021.

Science

Jun 4, 2022

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation

Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adjuvant setting.

Science

Mar 17, 2022

Genome Alert!: A standardized procedure for genomic variant reinterpretation and automated gene–phenotype reassessment in clinical routine

Retrospective interpretation of sequenced data in light of the current literature is a major concern of the field. Such reinterpretation is manual and both human resources and variable operating procedures are the main bottlenecks.

Science

Jun 23, 2021

Kmerator Suite: design of specific k-mer signatures and automatic metadata discovery in large RNA-seq datasets

The huge body of publicly available RNA-sequencing (RNA-seq) libraries is a treasure of functional information allowing to quantify the expression of known or novel transcripts in tissues.

Science

Sep 26, 2020

Clinical and Molecular Spectrum of Nonsyndromic Early-Onset Osteoarthritis

Osteoarthritis (OA) is the most common joint disease worldwide. The etiology of OA is varied, ranging from multifactorial to environmental to monogenic.

Science

Dec 28, 2017

DE-kupl: exhaustive capture of biological variation in RNA-seq data through k-mer decomposition

We introduce a k-mer-based computational protocol, DE-kupl, for capturing local RNA variation in a set of RNA-seq libraries, independently of a reference gen...

Science

Sep 29, 2017

SimBA: A methodology and tools for evaluating the performance of RNA-Seq bioinformatic pipelines

The evolution of next-generation sequencing (NGS) technologies has led to increased focus on RNA-Seq. Many bioinformatic tools have been developed for RNA-Seq analysis, each with unique performance characteristics and configuration parameters.